Moderna, Inc. (MRNA)

I want you to think about how quickly the long end of the U.S. Treasury curve is moving.

A year ago the stock market was flying high, only to plummet with the spread of a deadly, mysterious virus; this is the story of how it found a bottom.

As an early vaccinator I can tell you that you can make money from these strange things provided you do them before everybody gets the jab.

No matter what you want to call it -- there are plenty of reasons to be bullish right now.

The forces that benefited shares of companies such as Peloton Interactive and Clorox may not sustain them once the impact of the virus subsides.

Why? Consistency.

The fact is that even if there is some compromise, the next fiscal stimulus package will be closer to $1.9 trillion than $600 billion.

Let's not kid ourselves that there is any longer some kind of relationship between price and value. Or fact and truth.

Wednesday afternoon the Fed's Federal Open Market Committee will publish the central bank's first official policy statement of 2021.

The revenue and earnings beats are nice but that's not what really got me fired up.

Will the vaccine will be a game changer? The charts are giving indications that J&J is ready to run.

Enroll the private sector that has the capability of vaccinating en masse and save the kingdom.

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

We are going to live again. You will dance in the aisle at some concert whose performer I have never heard of, and you will cheer for your favorite team in person again.

The vaccine rollout has been bungled and the nation's in crisis, but you can either dwell on the negativity or look to ingenuity and opportunity. Here's where I see the latter.

A correction in EBS could soon set up an attractive opportunity.

This Friday several banks begin the unofficial kickoff of 'earnings season'.

I will have to give some of my favorite tech names a haircut in the name of balance. Hopefully everyone gained some exposure to gold.

As we move through Georgia and see an end in sight to Covid, we need a gut check on what stocks are really going to go the distance.

While there are certainly some things to like about AZN, I don't think this vaccine, nor the UK emergency authorization, make it investable.

I did something on Tuesday that I never thought that I would do again. I bought some Intel.

Cyber hacking, Covid mutations and other pressures are weighing on the market -- so this is what to do now.

Are traders working this holiday shortened week? You bet they are.

Let's look at the cold, hard facts around the vaccine rollout.

Plus, Coinbase files for an eventual initial public offering that should draw a ton of interest.

The stock hasn't done much of late, but perhaps FedEx's earnings report Thursday will offer clues of what's going on in delivery.

The Russell 2000 is now up 7% for December, twice the increase for the Nasdaq Composite.